Pfizer and biontech receive u.s. fda emergency use authorization for omicron ba.4/ba.5-adapted bivalent covid-19 vaccine booster in children 5 through 11 years of age

New york and mainz, germany, october 12, 2022 — pfizer inc. (nyse: pfe) and biontech se (nasdaq: bntx) today announced that the u.s. food and drug administration (fda) granted emergency use authorization (eua) for a 10-Μg booster dose of their omicron ba.4/ba.5-adapted bivalent covid-19 vaccine in children 5 through 11 years of age. pending recommendation from the centers for disease control and prevention (cdc), 10-Μg doses will be shipped immediately.
BNTX Ratings Summary
BNTX Quant Ranking